[Skip to Navigation]
Sign In
Case Report/Case Series
July 2013

Autoantibodies in Sporadic Creutzfeldt-Jakob Disease

Author Affiliations
  • 1Clinical Neurosciences, Royal Free London NHS Foundation Trust and Barnet Chase Farm Hospitals NHS Trust, London, England
  • 2MRC Prion Unit and National Prion Clinic, National Hospital for Neurology and Neurosurgery, London, England
  • 3Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, England
JAMA Neurol. 2013;70(7):919-922. doi:10.1001/jamaneurol.2013.2077

Importance  The diagnosis of autoimmune and neurodegenerative conditions can be unclear. Treatments such as removing the associated tumor, if present, and immunosuppression can halt or often reverse the progression of autoimmune conditions, but there is no curative treatment for neurodegenerative conditions. The presence of autoantibodies can sometimes be misleading. This report illustrates potential difficulties in differentiating autoimmune encephalopathies from sporadic Creutzfeldt-Jakob disease.

Observations  In a clinical follow-up of an older man with rapidly evolving encephalopathy at a neuroscience center, unsuccessful treatment with immunosuppression based on the incorrect presumptive diagnosis of Morvan syndrome was followed by the correct histological diagnosis of sporadic Creutzfeldt-Jakob disease.

Conclusions and Relevance  Autoimmune encephalopathies raise important treatment options and potential for recovery. However, since neuronal antibodies may be positive in prion disease, interpretation can be complex and must be rooted in the clinical picture.

Rapidly progressive neurological and cognitive syndromes are a complex diagnostic problem. The differential diagnosis includes inflammatory encephalopathies due to infective agents and immune-mediated disorders (both with and without remote neoplasia), central nervous system tumors, cerebral vasculitis, and rare neurodegenerative diseases such as the prion disease Creutzfeldt-Jakob disease (CJD). Imaging, neurophysiological, blood, and cerebrospinal fluid investigations usually confirm the clinical diagnosis rapidly, but there remains a small subgroup of patients in whom the diagnosis is unclear. This applies particularly to autoimmune and neurodegenerative conditions. It is of utmost importance to diagnose autoimmune conditions as treatments such as removing the associated tumor, if present, and immunosuppression can halt or often reverse progression, while there is no curative treatment for neurodegenerative conditions. The advances in detecting antibodies in these autoimmune diseases have been of great value in diagnosis, but their presence can sometimes be misleading. The following case report illustrates some of the issues encountered when differentiating a possible autoimmune encephalopathy from sporadic CJD (sCJD).

Report of a Case

A 68-year-old retired male taxi driver was admitted to the hospital in June 2011 with a 2-year history of progressive insomnia. Three months before admission, he developed personality change characterized by irritability, severe insomnia, “muscle spasms” in the legs, and a burning sensation in the feet, and then a progressive ataxia of gait culminating in a fall precipitating admission. He had a history of type 2 diabetes mellitus, coronary artery disease, porcine aortic valve replacement, and pacemaker insertion.

On admission, the patient was oriented and talkative, with a Mini-Mental State Examination score of 27 of 30. He performed poorly on tests of frontal lobe function, but more posterior functions were preserved. He had a pout reflex, increased tone of neck extensors, marked limb ataxia and apraxia, myoclonus without startle, myokymia, reduced reflexes, and flexor plantar responses.

During the next 2 months, he became chair bound and increasingly confused. The myokymia decreased during the next 2 months and had disappeared by 3 months. From July to August 2011, the patient had episodes of profuse sweating. Startle myoclonus was evident from 2 months, but this also abated by 3 to 4 months to be replaced by dystonia and subsequently choreoathetosis, both of which were markedly stimulus sensitive. There was considerable fluctuation in this period, with reported recognition of family members on only some occasions; this was complicated by 2 episodes of life-threatening septic shock. By 4 months from onset, he was bed bound, dysarthric, and dysphasic. Within 5 months, he was mute, with marked contractures and wasting, but pursuit eye movements were preserved until 8 months after admission. He died 9 months after the first neurological review.


Findings on routine hematological and biochemical investigations were normal. A vasculitis screen was negative. Computed tomography of the head (in July and November 2011) showed mild frontal atrophy. Magnetic resonance imaging of the brain could not be done because of the pacemaker. Electroencephalographic findings were normal from June to August 2011; thereafter, electroencephalography showed progressive slowing, ultimately displaying only delta rhythm in January 2012. Electromyographic findings in July 2011 showed myokymia, without neuropathy or denervation. The myokymia was no longer present clinically or on electromyography 3 months later. The following were found on cerebrospinal fluid examination: acellular; protein level of 0.61 g/L; normal glucose level; oligoclonal bands negative; S-100b protein level of 4.5 ng/mL (reference range, <0.4 ng/mL); and 14-3-3 protein positive. Prion protein gene (PRNP) sequencing revealed no mutations, with valine homozygosity at codon 129.

Antibody Testing

At 2 months, serum antibodies to the voltage-gated potassium channel complex (VGKC complex) were positive (210pM; reference range <100pM) and glycine receptor (GlyR) antibodies were also detectable; N-methyl-d-aspartate, glutamic acid decarboxylase, and paraneoplastic antibodies were all negative. The VGKC-complex antibodies were absent by the following month, but the GlyR antibodies had increased moderately (Figure). Cerebrospinal fluid was negative for both antibodies.

Figure.  Antibody Findings and Histopathological Analysis
Antibody Findings and Histopathological Analysis

A, Serum voltage-gated potassium channel complex antibodies (VGKC Ab) and glycine receptor antibodies (GlyR Ab) during the course of the illness. The cutoff values for healthy subjects are indicated by a dashed line. *Negative cerebrospinal fluid titers of each antibody. Treatment modality durations and a summary of symptom development are shown. IVIg indicates intravenous immunoglobulin. B, Typical spongiform change in frontal biopsy (hematoxylin-eosin, scale bar = 100 μm). C, Abnormal prion protein immunoreactivity in the biopsy specimen of the frontal brain showing synaptic distribution with ICSM35 monoclonal antibody (scale bar = 100 μm).

Right Frontal Brain Biopsy

Biopsy of the right frontal brain was performed on January 20, 2012. There was severe transcortical spongiform change with severe neuronal depletion and extensive gliosis. Immunocytochemistry using ICSM35 antibody1 demonstrated dense prion staining predominantly of synaptic type. There were foci of AT8 immunoreactivity (β-amyloid) without neurofibrillary tangles and a few short tau-positive threads. No lymphocytic infiltrates were found, and the appearances were of definite sCJD.


Sepsis was successfully treated with fluid resuscitation and antibiotics. Symptomatic treatment with clonazepam, co-careldopa, and baclofen did not help the rigidity; botulinum toxin injections reduced lower limb spasticity.

In the presence of positive VGKC-complex and GlyR antibodies, immunosuppressant treatment with steroids, intravenous immunoglobulin, plasma exchange, and cyclophosphamide was commenced (Figure). There was no sustained improvement, although eye contact improved for 10 days following plasma exchange.

The major clinical features together with antibody levels are illustrated in the Figure.


The presenting picture of rapid-onset personality change, insomnia, associated myokymia and myotonia, ataxia, apraxia, and initially relatively preserved cognitive function was more in keeping with Morvan syndrome2 than sCJD. This presumptive diagnosis was supported by the presence of VGKC-complex antibodies in the serum at levels that, although relatively low (210pM), are consistent with this diagnosis.2 Positive GlyR antibodies3 further suggested an immune basis for the patient’s symptoms. There are previous reports of limbic encephalitis with VGKC-complex antibodies misdiagnosed as sCJD,4 so it was important to seriously consider an immune basis for his condition. Many of the recently described immune-mediated encephalopathies are potentially treatable, particularly those with neuronal surface–directed antibodies5; thus, rapid diagnosis and treatment are essential if viable neurons are to be salvaged.5,6 However, intensive treatments to remove the antibodies were performed without clear benefit. After considerable delay due to episodes of sepsis, a cerebral biopsy was performed. It showed conclusive evidence of sCJD, with the PRNP sequencing showing no mutations.7

What could account for the finding of the antibodies in a case of sCJD? Apart from the remote possibility of extremely rare conditions occurring simultaneously, there was no evidence of an inflammatory encephalopathy at biopsy,6 although it is possible that the inflammatory process was focused on other brain regions or had resolved by this time. Are the antibodies false-positive? Antibodies to the VGKC complex in the range of 100pM to 400pM are detected in up to 5% of community controls older than 65 years.5 Antibodies to LGI1 and CASPR2, the principal known components of the VGKC complex,5 were negative in our patient. This does not exclude the presence of cell surface–binding antibodies to as yet undefined components of the VGKC complex (A.V., unpublished data, 2012). Insomnia, burning pain, myokymia, and myotonia are features of Morvan syndrome2 and, apart from insomnia, are infrequent in sCJD.8 Equally, although also at low to moderate levels in this patient, GlyR antibodies (<2% in controls3) are associated with myoclonus and rigidity,3 which were striking features in our patient. It seems likely that the rapid destruction of cerebral tissue by prion disease released neuronal antigens, leading to development of the antibodies as secondary events. The temporal relationship of the antibodies to the clinical features suggests that they may have contributed to the pathophysiology.

Several other factors complicated the diagnosis in this case. Magnetic resonance imaging is valuable in sCJD, where signal return from the basal ganglia and cortical ribbon on diffusion-weighted imaging sequences has a high sensitivity and specificity,9,10 but our patient’s pacemaker precluded this investigation and the results can occasionally be found in other conditions. The positive cerebrospinal fluid markers present in our case occur in sCJD but are also not disease specific.11 The patient did not have the typical periodic complexes on electroencephalography described in about two-thirds of patients with sCJD.12

This case illustrates the difficulty in determining the etiology of rapidly progressive encephalopathies and that laboratory tests can be misleading and do not exclude a neurodegenerative disease. There are also 2 recent reports of N-methyl-d-aspartate receptor antibodies in sCJD.13,14 A prospective study is required to ascertain the frequency of neuronal antibodies in sCJD and other rapidly progressive neurodegenerative diseases. When titers of neuronal antibodies are increased in a patient with a progressive encephalopathy, it is reasonable to treat with immunosuppression because of the potential benefit. At the same time, an open mind to the differential diagnosis should be maintained throughout the course of rapidly progressive encephalopathies, as the classic cerebrospinal fluid markers, imaging, and antibody tests are not pathognomonic.

Back to top
Article Information

Accepted for Publication: December 6, 2012.

Corresponding Author: Heather Angus-Leppan, MD, FRCP, Clinical Neurosciences, Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, England (heather.angus-leppan@nhs.net).

Published Online: May 13, 2013. doi:10.1001/jamaneurol.2013.2077

Author Contributions: Drs Angus-Leppan and Rudge had full access to all the data in this study and take responsibility for the integrity of the data and accuracy of the data analysis.

Study concept and design: Angus-Leppan, Rudge, and Mead.

Acquisition of data: Angus-Leppan, Rudge, Mead, and Vincent.

Analysis and interpretation of data: Angus-Leppan, Collinge, and Vincent.

Drafting of the manuscript: Angus-Leppan, Rudge, and Collinge.

Critical revision of the manuscript for important intellectual content: All authors.

Administrative, technical, and material support: Angus-Leppan, Rudge, and Mead.

Study supervision: Rudge, Mead, and Collinge.

Conflict of Interest Disclosures: Dr Collinge is a director and shareholder of D-Gen Limited, an academic spin-out company working in the field of prion disease diagnosis, decontamination, and therapeutics. D-Gen markets the ICSM35 antibody used in this study. Dr Vincent and the University of Oxford hold patents and receive royalties and payments for antibody assays.

Additional Contributions: We thank the patient’s family, who encouraged us to publish this case report. We are grateful to the Oxford National Institute for Health Research Biomedical Research Centre for support, to Drs M. Woodhall and L. Jacobson for the antibody tests, and to Prof Sebastian Brandner for the histological studies.

Khalili-Shirazi  A, Quaratino  S, Londei  M,  et al.  Protein conformation significantly influences immune responses to prion protein.  J Immunol. 2005;174(6):3256-3263.PubMedGoogle Scholar
Irani  SR, Pettingill  P, Kleopa  KA,  et al.  Morvan syndrome: clinical and serological observations in 29 cases.  Ann Neurol. 2012;72(2):241-255.PubMedGoogle ScholarCrossref
Mas  N, Saiz  A, Leite  MI,  et al.  Antiglycine-receptor encephalomyelitis with rigidity.  J Neurol Neurosurg Psychiatry. 2011;82(12):1399-1401.PubMedGoogle ScholarCrossref
Geschwind  MD, Tan  KM, Lennon  VA,  et al.  Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease.  Arch Neurol. 2008;65(10):1341-1346.PubMedGoogle ScholarCrossref
Vincent  A, Bien  CG, Irani  SR, Waters  P.  Autoantibodies associated with diseases of the CNS: new developments and future challenges.  Lancet Neurol. 2011;10(8):759-772.PubMedGoogle ScholarCrossref
Bien  CG, Vincent  A, Barnett  MH,  et al.  Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis.  Brain. 2012;135(pt 5):1622-1638.PubMedGoogle ScholarCrossref
Lloyd  S, Mead  S, Collinge  J.  Genetics of prion disease.  Top Curr Chem. 2011;305:1-22.PubMedGoogle Scholar
Ishida  C, Okino  S, Kitamoto  T, Yamada  M.  Involvement of the peripheral nervous system in human prion diseases including dural graft associated Creutzfeldt-Jakob disease.  J Neurol Neurosurg Psychiatry. 2005;76(3):325-329.PubMedGoogle ScholarCrossref
Zerr  I, Kallenberg  K, Summers  DM,  et al.  Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease.  Brain. 2009;132(pt 10):2659-2668.PubMedGoogle ScholarCrossref
Hyare  H, Thornton  J, Stevens  J,  et al.  High-b-value diffusion MR imaging and basal nuclei apparent diffusion coefficient measurements in variant and sporadic Creutzfeldt-Jakob disease.  AJNR Am J Neuroradiol. 2010;31(3):521-526.PubMedGoogle ScholarCrossref
Skinningsrud  A, Stenset  V, Gundersen  AS, Fladby  T.  Cerebrospinal fluid markers in Creutzfeldt-Jakob disease.  Cerebrospinal Fluid Res. 2008;5:14.PubMedGoogle ScholarCrossref
Steinhoff  BJ, Räcker  S, Herrendorf  G,  et al.  Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease.  Arch Neurol. 1996;53(2):162-166.PubMedGoogle ScholarCrossref
Mackay  G, Ahmad  K, Stone  J,  et al.  NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease.  J Neurol. 2012;259(9):1979-1981.PubMedGoogle ScholarCrossref
Fujita  K, Yuasa  T, Takahashi  Y,  et al.  Antibodies to N-methyl-D-aspartate glutamate receptors in Creutzfeldt-Jakob disease patients.  J Neuroimmunol. 2012;251(1-2):90-93.PubMedGoogle ScholarCrossref